{"public_id":"co_f04b81076e596c1d1b18b92bdbfde082","status":"active","merged_into_public_id":null,"resolved_public_id":"co_f04b81076e596c1d1b18b92bdbfde082","name":"imatinib","description":"A c-Abl and Arg inhibitor examined here for effects on chemoresistance pathways in cancer cells.","aliases":["imatinib mesylate","STI571","Gleevec"],"types":["drug","inhibitor"],"contributors":[{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["extraction"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["review"],"url":"https://sah.borca.ai/u/322360f1c1"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":13587391,"title":"Imatinib Reverses Doxorubicin Resistance by Affecting Activation of STAT3-Dependent NF-κB and HSP27/p38/AKT Pathways and by Inhibiting ABCB1","citation_count":110,"url":"https://sah.borca.ai/papers/13587391"}],"claims":[{"public_id":"cl_5d2ac549cf7ebb4510f1c989da3a9dad","text":"Imatinib prevents intrinsic doxorubicin resistance by promoting doxorubicin-mediated NF-κB/p65 nuclear localization and repression of NF-κB targets in a STAT3-dependent manner.","corpus_id":13587391,"url":"https://sah.borca.ai/claims/cl_5d2ac549cf7ebb4510f1c989da3a9dad"},{"public_id":"cl_a8e1ed5f343542e651d442d006f290a7","text":"Imatinib prevents intrinsic doxorubicin resistance by blocking activation of a STAT3/HSP27/p38/Akt survival pathway.","corpus_id":13587391,"url":"https://sah.borca.ai/claims/cl_a8e1ed5f343542e651d442d006f290a7"},{"public_id":"cl_ca1ef6066ff76652f5240335e6f13e81","text":"Imatinib reverses intrinsic and acquired resistance to doxorubicin by inducing G2/M arrest and promoting apoptosis in cancer cells with highly active c-Abl and Arg.","corpus_id":13587391,"url":"https://sah.borca.ai/claims/cl_ca1ef6066ff76652f5240335e6f13e81"},{"public_id":"cl_d359934d7de60c3665ce8701a8f3a359","text":"Imatinib prevents acquired doxorubicin resistance by inhibiting ABCB1 upregulation, directly inhibiting ABCB1 function, and abrogating survival signaling.","corpus_id":13587391,"url":"https://sah.borca.ai/claims/cl_d359934d7de60c3665ce8701a8f3a359"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_f04b81076e596c1d1b18b92bdbfde082","url":"https://sah.borca.ai/concepts/co_f04b81076e596c1d1b18b92bdbfde082"}